trial · primary record
Lung cancer-specific T cells
Lung Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 20 |
| Primary completion | 2030-12-31 |
| Primary endpoint | Safety of engineered T cells in patients using CTCAE version 4.0 standard to evaluate the level of adverse events |
| Registry ID | NCT03356808 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:42:37.636Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03356808
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.